These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 23142635)

  • 81. Inhaled antibodies: Quality and performance considerations.
    Hickey AJ; Stewart IE
    Hum Vaccin Immunother; 2022 Apr; 18(2):1940650. PubMed ID: 34191682
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Non-invasive systemic drug delivery: developability considerations for alternate routes of administration.
    Mathias NR; Hussain MA
    J Pharm Sci; 2010 Jan; 99(1):1-20. PubMed ID: 19499570
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Nanotechnology approaches for inhalation treatment of lung diseases.
    Kuzmov A; Minko T
    J Control Release; 2015 Dec; 219():500-518. PubMed ID: 26297206
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Single Batch Bioequivalence Paradigm for Orally Inhaled Products: Time for Change.
    Hermann R; Olsson B; Borgström L; Sandell D
    Clin Pharmacol Ther; 2018 Mar; 103(3):395. PubMed ID: 29238955
    [No Abstract]   [Full Text] [Related]  

  • 85. Current Understanding of the Equivalence Evaluations for In Vitro Tests on Generic Dry Powder Inhaler Drug Products in Japan.
    Kuribayashi R; Myoenzono A; Takagi K; Hirota M
    Eur J Drug Metab Pharmacokinet; 2019 Dec; 44(6):743-745. PubMed ID: 31062276
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Inhaled proteins: challenges and perspectives.
    Depreter F; Pilcer G; Amighi K
    Int J Pharm; 2013 Apr; 447(1-2):251-80. PubMed ID: 23499756
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Pharmacokinetic/pharmacodynamic approaches to drug delivery design for inhalation drugs.
    Matera MG; Calzetta L; Ora J; Rogliani P; Cazzola M
    Expert Opin Drug Deliv; 2021 Jul; 18(7):891-906. PubMed ID: 33412922
    [No Abstract]   [Full Text] [Related]  

  • 88. Overview of Brazilian Requirements for Therapeutic Equivalence of Orally Inhaled and Nasal Drug Products.
    Silva MC; Costa HS; Valadares BN; Grecchi L; Nagao L; Santos GML
    AAPS PharmSciTech; 2019 Jun; 20(6):235. PubMed ID: 31236849
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Pharmacokinetics of Orally Inhaled Drug Products.
    Hochhaus G; Horhota S; Hendeles L; Suarez S; Rebello J
    AAPS J; 2015 May; 17(3):769-75. PubMed ID: 25762449
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Multiscale Co-reconstruction of Lung Architectures and Inhalable Materials Spatial Distribution.
    Sun X; Zhang X; Ren X; Sun H; Wu L; Wang C; Ye X; York P; Gao Z; Jiang H; Zhang J; Yin X
    Adv Sci (Weinh); 2021 Apr; 8(8):2003941. PubMed ID: 33898181
    [TBL] [Abstract][Full Text] [Related]  

  • 91. In Vitro Testing for Orally Inhaled Products: Developments in Science-Based Regulatory Approaches.
    Forbes B; Bäckman P; Christopher D; Dolovich M; Li BV; Morgan B
    AAPS J; 2015 Jul; 17(4):837-52. PubMed ID: 25940082
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Contemporary Formulation Development for Inhaled Pharmaceuticals.
    Sou T; Bergström CAS
    J Pharm Sci; 2021 Jan; 110(1):66-86. PubMed ID: 32916138
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Inhalation Biopharmaceutics: Progress Towards Comprehending the Fate of Inhaled Medicines.
    Ehrhardt C
    Pharm Res; 2017 Dec; 34(12):2451-2453. PubMed ID: 29147818
    [No Abstract]   [Full Text] [Related]  

  • 94. Inhaled Medicines: Past, Present, and Future.
    Anderson S; Atkins P; Bäckman P; Cipolla D; Clark A; Daviskas E; Disse B; Entcheva-Dimitrov P; Fuller R; Gonda I; Lundbäck H; Olsson B; Weers J
    Pharmacol Rev; 2022 Jan; 74(1):48-118. PubMed ID: 34987088
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications.
    Labiris NR; Dolovich MB
    Br J Clin Pharmacol; 2003 Dec; 56(6):588-99. PubMed ID: 14616418
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Current Scientific and Regulatory Approaches for Development of Orally Inhaled and Nasal Drug Products: Overview of the IPAC-RS/University of Florida Orlando Inhalation Conference.
    Hochhaus G; Davis-Cutting C; Oliver M; Lee SL; Lyapustina S
    AAPS J; 2015 Sep; 17(5):1305-11. PubMed ID: 26033698
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Clinically Relevant In Vitro Testing of Orally Inhaled Products-Bridging the Gap Between the Lab and the Patient.
    Mitchell JP; Suggett J; Nagel M
    AAPS PharmSciTech; 2016 Aug; 17(4):787-804. PubMed ID: 27173990
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Thermostable Subunit Vaccines for Pulmonary Delivery: How Close Are We?
    Foged C
    Curr Pharm Des; 2016; 22(17):2561-76. PubMed ID: 26831645
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Symposium Summary: "Breathe In, Breathe Out, Its Easy: What You Need to Know About Developing Inhaled Drugs".
    Tepper JS; Kuehl PJ; Cracknell S; Nikula KJ; Pei L; Blanchard JD
    Int J Toxicol; 2016 Jul; 35(4):376-92. PubMed ID: 26857693
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Inhalable PEGylated Phospholipid Nanocarriers and PEGylated Therapeutics for Respiratory Delivery as Aerosolized Colloidal Dispersions and Dry Powder Inhalers.
    Muralidharan P; Mallory E; Malapit M; Hayes D; Mansour HM
    Pharmaceutics; 2014 Jun; 6(2):333-53. PubMed ID: 24955820
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.